Medical Device Developments的动态

Complex SFA recanalisation procedure in CLTI with Ashish Patel from Guy's and St Thomas' NHS Foundation Trust during VIO 2023. Moderated by Marie Josee van Rijn joined by Venita Chandra, Gregory Stanley MD FACS, Leigh Ann O'Banion and Elizabeth Genovese, MD, MS, FACS, RPVI The iliac artery was crossed quickly during the procedure, and a six French sheath was placed for access. The main challenge identified was a flush occlusion of the superficial femoral artery (SFA), requiring careful navigation. A Gladius wire by intend was used to manage the occlusion. This wire helped navigate through the challenging blockage. Intravascular Ultrasound (IVUS) was employed with minimal contrast to visualize the arterial disease, showing a significant SFA occlusion and some involvement of the profunda femoris. The procedure aimed at re-establishing blood flow in the SFA, critical in managing CLTI, and the Gladius wire and IVUS were central in achieving this goal. #viocongress #vascular #PAD #SFA ASAHI INTECC Europe B.V. Philips

We were thrilled to be part of?ESC 2024, where over?30,000 cardiologists?gathered to explore the latest advancements in cardiovascular care. At the event, we proudly showcased our?BioScan touch i8, an innovative medical device for?early, non-invasive assessment of congestive and decompensated heart failure. The response to our technology was overwhelming, as healthcare professionals discovered how the?BioScan touch i8?can deliver real-time, actionable insights into fluid management and heart function—helping improve patient outcomes with precision and speed. Evidence based: ? ESC Heart Failure 2023; 10: 2418–2426 Published online 24 May 2023 in Wiley Online Library DOI: 10.1002/ehf2.14398 ? “Among overweight and obese patients with HF, BioScan touch i8 BIA reduces NT-proBNP levels at 90 days compared with standard care. In addition, there is a trend towards lower incidence of AKI in the BioScan touch i8 BIA-guided group”. ? Missed us at ESC? Stay connected for more updates on how we're transforming heart failure management! #ESC2024 #BioScanTouchi8 #CardiologyInnovation #HeartFailureCare www.maltronint.com

We were thrilled to be part of?ESC 2024, where over?30,000 cardiologists?gathered to explore the latest advancements in cardiovascular care. At the event, we proudly showcased our?BioScan touch i8, an innovative medical device for?early, non-invasive assessment of congestive and decompensated heart failure. The response to our technology was overwhelming, as healthcare professionals discovered how the?BioScan touch i8?can deliver real-time, actionable insights into fluid management and heart function—helping improve patient outcomes with precision and speed. Evidence based: ? ESC Heart Failure 2023; 10: 2418–2426 Published online 24 May 2023 in Wiley Online Library DOI: 10.1002/ehf2.14398 ? “Among overweight and obese patients with HF, BioScan touch i8 BIA reduces NT-proBNP levels at 90 days compared with standard care. In addition, there is a trend towards lower incidence of AKI in the BioScan touch i8 BIA-guided group”. ? Missed us at ESC? Stay connected for more updates on how we're transforming heart failure management! #ESC2024 #BioScanTouchi8 #CardiologyInnovation #HeartFailureCare www.maltronint.com

We were thrilled to be part of?ESC 2024, where over?30,000 cardiologists?gathered to explore the latest advancements in cardiovascular care. At the event, we proudly showcased our?BioScan touch i8, an innovative medical device for?early, non-invasive assessment of congestive and decompensated heart failure. The response to our technology was overwhelming, as healthcare professionals discovered how the?BioScan touch i8?can deliver real-time, actionable insights into fluid management and heart function—helping improve patient outcomes with precision and speed. Evidence based: ? ESC Heart Failure 2023; 10: 2418–2426 Published online 24 May 2023 in Wiley Online Library DOI: 10.1002/ehf2.14398 ? “Among overweight and obese patients with HF, BioScan touch i8 BIA reduces NT-proBNP levels at 90 days compared with standard care. In addition, there is a trend towards lower incidence of AKI in the BioScan touch i8 BIA-guided group”. ? Missed us at ESC? Stay connected for more updates on how we're transforming heart failure management! #ESC2024 #BioScanTouchi8 #CardiologyInnovation #HeartFailureCare www.maltronint.com

Sanjay Patel shares some insights on Shockwave Medical's intravascular Lithotripsy (IVL) during a live case on SFA disease and supera stenting, performed by Narayanan Thulasidasan at Guy's and St Thomas' NHS Foundation Trust. Live case was moderated by Nicos Labropoulos, joined by Dr Michael Lichtenberg, MD, MD, Maria Antonella Ruffino, MD, EBIR, FCIRSE & Mary Costantino, MD. Sizing is one of the critical factors to think about during the procedure. Proper sizing ensures better results, particularly in terms of device performance and patient outcomes. A key element for success in the procedure is achieving good wall apposition. This ensures that the stent or device adheres properly to the vessel wall, which improves long-term effectiveness. The procedure relies on the transmission of ultrasonic waves through dense masses. This is particularly useful when dealing with calcification in the vessels. The ultrasonic waves from the IVL device are transmitted first through water and contrast within the balloon, and then onto the vessel wall, breaking up the calcified deposits. Calcification is a significant challenge in the treatment of SFA disease, and tools like IVL are crucial in managing these cases by disrupting calcified areas effectively before stenting. #viocongress #PAD #SFA

CT Coronary Angiogram Explained - A Simplified Insight through Mr. Hypothetical's Experience This article aims to demystify the CT Coronary Angiogram (CTCA) using the story of a hypothetical patient, Mr. Hypothetical. CTCA is a specialized imaging technique that uses computed tomography (CT) to provide detailed images of the coronary arteries. It’s important to note that CTCA is not a routine screening tool but is used based on individual health assessments, considering specific risk factors and symptoms. CTCA Technology: CTCA employs advanced CT technology along with a contrast dye, iodine-based, injected into the bloodstream. This dye highlights the coronary arteries on the CT scan, enabling the visualization of plaque or any vessel anomalies. Mr. Hypothetical’s Journey: Mr. Hypothetical, 50, a corporate professional, experienced stress-related symptoms which led his doctor to recommend a CTCA to check for coronary artery disease. Preparation and Procedure: Prior to the CTCA, he was advised to avoid heavy meals and Viagra like medications. On the day, Mr. Hypothetical arrived at the clinic and was briefed about the procedure, which eased his anxiety. He then changed into a hospital gown and prepared for the scan. An IV line was inserted for contrast administration, and medication was given to control his heart rate which took about an hour During the Scan: Sublingual nitroglycerin was administered before the 15-minute scan to dilate his coronary arteries. He experienced a warm sensation from the dye, which is common. Post-Procedure: After the scan, Mr. Hypothetical was monitored for 30 minutes. The total duration of his clinic visit was about 4 hours. He received his results, indicating mild plaque buildup but no significant blockage, the next day. This led to a consultation on lifestyle changes and potential medical interventions. It underscores the importance of heeding our body's signals and proactively seeking expert medical evaluation. #patientcenteredcare #preventivehealthcare #CardiacHealth #CTCA #MedicalInnovation #HeartDiseaseAwareness Top of Form

February is Age-Related Macular Degeneration (AMD) Awareness Month! - Check out this article in MED-Midwest Medical Edition about AMD.

Now presenting at #InnovationDublin24 is ORIXHA with CEO Fabrice PAUBLANT. ? Orixha’s (Maisons-Alfort, France) mission is to develop Liquid Ventilation Medical Devices to save lives in Critical Care. Orixha develops Vent2Cool based on its proprietary Lung Conservative Liquid Ventilation to shield the critical organs (brain, heart) from reperfusion injury.?Vent2Cool improves survival and morbidity outcomes of Post Cardiac Arrest Syndrome by transforming the lungs into an efficient heat exchanger with the circulating blood to induce ultra-rapid therapeutic hypothermia – reaching the 33°C protective temperature within minutes vs. hours with current hypothermia devices. Orixha’s proprietary total liquid ventilation technology platform, once validated in therapeutic hypothermia, will be developed for other Critical Care conditions such as Acute Respiratory Distress Syndrome. Orixha is disrupting the critical care landscape for the ventilation of patients with cardiac arrest and respiratory distress. Orixha’s unique approach delivers total liquid ventilation, resting the alveoli and avoiding inflammatory stress in the lungs.?? ? Remain informed on new articles, conference updates and more with our helpful medtech community newsletter. Subscribe here: https://bit.ly/42KHJKI

Could different LBBAP capture sites lead to a different outcomes in heart failure (HF) patients ? ? ?? First insights from an elegant study published in Heart Rhythm Journal. ? ?? Design: 43 consecutive HF patients, referred for LBBAP implantation were assigned to 3 subgroups according to the paced QRS complex morphology: left bundle branch trunk pacing, left posterior fascicular pacing, or left anterior fascicular pacing groups. ?? Results: After 6 months, all subgroups were efficient in narrowing QRS complex and improving cardiac function. However, Patients who paced on the main trunk of the LBB rather than a specific fascicle were more likely to achieve higher cardiac function improvement. ?? For more info: https://lnkd.in/dJTuJR4c #LBBAP

#ESCCongress 2024 in London is just two weeks away! Visit our booth and discover how the #MESImTABLET diagnostic system unlocks the full potential of cardiovascular diagnostics. ???Interconnected diagnostic tools on one device:?12-lead resting ECG, E monitor (with additional Dual Blood Pressure and Averaging Blood Pressure apps), Ankle-Brachial Index, SPO2 and so much more. ???6-Minute Walk Test (6MWT): effective exams with instant data saving and patient’s trends overview. ??Seamless EHR integration:?The MESI mTABLET system can be easily integrated into your existing medical administration system for effective workflow. European Society of Cardiology ExCeL London